The Human Cytomegalovirus–Encoded Chemokine Receptor US28 Promotes Angiogenesis and Tumor Formation via Cyclooxygenase-2

David Maussang,¹ Ellen Langemeijer,¹ Carlos P. Fitzsimons,¹ Marijke Stigter-van Walsum,² Remco Dijkman,¹ Martin K. Borg,¹ Erik Slinger,¹ Andreas Schreiber,¹ Detlef Michel,³ Cornelis P. Tensen,¹ Guus A.M.S. van Dongen,³ Rob Leurs,¹ and Martine J. Smit¹

¹Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit Amsterdam; 2Department of Otolaryngology/Head and Neck Surgery, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; ³Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands; and 4Institute of Virology, University Clinic Ulm, Ulm, Germany

Abstract

The human cytomegalovirus (HCMV), potentially associated with the development of malignancies, encodes the constitutively active chemokine receptor US28. Previously, we have shown that US28 expression induces an oncogenic phenotype both in vitro and in vivo. Microarray analysis revealed differential expression of genes involved in oncogenic signaling in US28-expressing NIH-3T3 cells. In particular, the expression of cyclooxygenase-2 (COX-2), a key mediator of inflammatory diseases and major determinant in several forms of cancer, was highly up-regulated. US28 induced increases in COX-2 expression via activation of nuclear factor-κB, driving the production of vascular endothelial growth factor. Also, in HCMV-infected cells, US28 contributed to the viral induction of COX-2. Finally, the involvement of COX-2 in US28-mediated tumor formation was evaluated using the COX-2 selective inhibitor Celecoxib. Targeting COX-2 in vivo with Celecoxib led to a marked delay in the onset of tumor formation in nude mice injected with US28-transfected NIH-3T3 cells and a reduction of subsequent growth by repressing the US28-induced angiogenic activity. Hence, the development of HCMV-related proliferative diseases may partially be ascribed to the ability of US28 to activate COX-2.

Introduction

Herpesviruses are widespread pathogens, which establish a lifelong latent and persistent infection. In immunocompetent hosts, infection is often asymptomatic, whereas reactivation can lead to serious pathologic conditions (1). In particular, γ-herpesviruses possess oncogenic potential, as they are able to transform cells upon infection (2). Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent of Kaposi’s sarcoma (3), whereas Epstein-Barr virus (EBV) is associated with lymphoproliferative diseases such as Burkitt’s lymphoma and Hodgkin’s disease (4). Unlike KSHV and EBV, the human cytomegalovirus (HCMV) is not considered an oncogenic herpesvirus (5), but it has been suggested to act as an oncomodulator (6). The presence of HCMV proteins has been detected in several malignancies, such as colon cancer (7), malignant glioblastoma (8), and breast cancer (9). Importantly, HCMV preferably infects tumor cells, leading to enhanced cell proliferation, angiogenesis, and resistance to apoptosis (6, 10).

Of interest, most herpesviruses contain one or more genes that encode for constitutively active G-protein coupled receptors (1). These viral G-protein coupled receptors show highest homology to the class of chemokine receptors, known to be involved in the control of the immune system but also the development of various types of cancer (11). As such, these viral G-protein coupled receptors likely contribute to viral pathogenesis. The KSHV-encoded G-protein coupled receptor ORF74 is believed to act as a viral oncoprotein and is considered a key determinant in the pathology of Kaposi’s sarcoma. ORF74 possesses proliferative, angiogenic, and antiapoptotic properties, and drives the cell-transforming properties of KSHV (12, 13). Recently, we have shown that the HCMV-encoded chemokine receptor US28, which can bind several chemokines (e.g., CCL2, CCL5, CX3CL1), constitutively activates various inflammatory and proliferative signaling pathways such as nuclear factor-κB (NF-κB) and induces tumor formation in vivo (14). Expression of US28 activates G<sub>q</sub>-linked signaling pathways, e.g., production of inositol phosphate (15), resulting in an increase in cyclin D1 expression, DNA synthesis, and secretion of vascular endothelial growth factor (VEGF; ref. 14). Mice injected with US28-expressing NIH-3T3 cells develop tumors with high VEGF expression. Moreover, an increase in VEGF promoter activity is also apparent in HCMV-infected glioblastoma cells, which can be attributed to the expression of US28 (14). Interestingly, US28 expression has also been detected during primary and secondary HCMV infection in immunosuppressed patients (16). Considering the pathogenic potential of HCMV in these patients, US28 expression at this stage may play a role in the progression of HCMV-linked proliferative diseases.

Profiling of the expression of thousands of genes by means of DNA microarrays has served to discover new oncogenes and potentially new targets for the treatment of cancer (17). It has also been used to understand molecular mechanisms underlying the development of herpesvirus associated diseases (18–20). To gain mechanistic insight into the oncogenic behavior of the HCMV-encoded chemokine receptor US28, we performed microarray analysis on US28 and mock-transfected cells. Various proteins involved in oncogenesis were found to be modulated by the expression of US28. In particular, cyclooxygenase-2 (COX-2) was highly up-regulated upon US28 expression. Also, in HCMV-infected...
cells, US28 contributed to the viral induction of COX-2. Finally, the COX-2–specific inhibitor Celecoxib did not only inhibit the up-regulation of VEGF in US28-expressing cells but also markedly decreased US28-induced tumor formation rate in nude mice. As such, US28 up-regulates COX-2 expression to promote tumor formation.

Materials and Methods

Cell culture. The mock (empty pcDEF3 expression vector) and US28 stably transfected NIH-3T3 cell lines were cultured as previously described (14). The human embryonic kidney cell line HEK 293T was cultured in DMEM containing 10% fetal bovine serum (FBS) and transfected using polyethylenimine. The human foreskin fibroblast BJ cell line was maintained in MEM (Eagle) with 2 mmol/L l-glutamine and Earle's balanced salt solution adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mmol/L nonessential amino acids, 1.0 mmol/L sodium pyruvate, and 10% FBS.

Chemokine binding and inositol phosphate accumulation experiments. Stably transfected NIH-3T3 cells and HCMV-infected BJ cells were analyzed for radiolabeled chemokine binding and inositol phosphate formation as previously described (14).

Microarray analysis. NIH-3T3 cells stably transfected with either mock or US28 were serum starved overnight with 0.5% calf serum containing medium. Total RNA was isolated from two independent clones for both cell lines with the RNeasy kit (Qiagen) followed by cDNA synthesis and overnight biotin-labeled cRNA amplification (MessageAmp II aRNA Amplification; Ambion). Twenty micrograms of biotin-labeled cRNA was hybridized to Affymetrix Mouse Genome 430 2.0 arrays and processed according to Affymetrix procedures. Arrays were normalized (RMA) and analyzed using LIMMA statistical package (21). The data have been deposited in National Center for Biotechnology Information’s Gene Expression Omnibus (22) and are accessible through GEO Series accession number GSE13567. Genes differentially expressed between mock and US28-transfected cells were selected based on stringent false discovery rates (false discovery rate, ≤0.02). The retrieved gene lists were analyzed with DAVID and EASE softwares (23, 24) and compared with lists of cancer-related genes6 and to NF-κB transcriptional targets.7

Quantitative real-time-PCR. For biological validation of microarray data by quantitative real-time-PCR (qPCR) analysis, total RNA was isolated from NIH-3T3 cells and from US28 xenografts using the RNeasy kit (Qiagen) and reverse transcribed using iScript cDNA synthesis kit (Bio-Rad), according to the manufacturers’ instructions. qPCR primers (from Invitrogen or Isogen) used are described in Supplementary Table S4. PCR reactions were performed using SYBR Green mix with MyIQ Real-Time PCR detection system (Bio-Rad). qPCR on HCMV-infected cells was performed with the ABI-Prism 7700 instrument and the SYBR Green PCR Master Mix (Applied Biosystems). Data were evaluated with the sequence detection software version 1.9.1 (Applied Biosystems) and the second derivative melt curve analysis. In addition to melting curve analysis, specificity of the PCR products were confirmed by running controls on agarose gel electrophoresis and subsequent DNA sequence analysis.

Luciferase reporter gene experiments. The NF-κB and VEGF promoter luciferase reporter genes were previously described (14, 15), and the wild-type (WT) and mutated COX-2 promoter luciferase reporter gene plasmids were obtained from Dr. M. Fresno (Universidad Autónoma de Madrid, Madrid, Spain; ref. 25). Luciferase activity was measured 24 h posttransfection.

Viral experiments. BJ cells were infected with the different HCMV virus strains (AD169-WT and AD169-US28; ref. 26) with a multiplicity of infection of 3, and the different assays were performed 8 h postinfection.

NF-κB activation was measured by transfecting cells with the NF-κB luciferase reporter gene 24 h before infection.

Western blot analysis. Quantification of COX-2 protein level was performed by Western blot on total cell lysates with a rabbit polyclonal COX-2 antibody (Cell Signaling Technology) and a mouse monoclonal β-actin antibody (Sigma).

In vivo experiment. All animal experiments were conducted according to the NIH principles of laboratory animal care and Dutch national law ["Wet op de Dierproeven" (5th 1985, 336)], approved by the Dierexperimentencommissie from the Vrije Universiteit Medical Center and performed in compliance with the protocol FaCh 05-02. US28 stably transfected NIH-3T3 cells (2 × 10³) were injected s.c. into the flanks of 8- to 10-wk-old female nude mice (Hsd, athymic nu/nu, 25–32 grams; Harlan Laboratories Cambridge Research Biochemicals). The control group was fed with regular mouse chow (Teklad Harlan), whereas the Celecoxib group was fed 1 d before the cell injection with mouse chow containing 1,500 ppm Celecoxib (Pfizer) ad libitum.

Immunohistochemistry. Cryosections of US28-induced xenografts were stained for the presence of CD31 using a rat anti-mouse CD31 antibody (BD Pharmingen) with a horseradish peroxidase-conjugated mouse anti-rat antibody (Zymed Laboratories).

Results

Microarray analysis of US28-expressing cells. Expression of the HCMV-encoded chemokine receptor US28 in NIH-3T3 cells induces increased cell growth and a proangiogenic phenotype (14). To gain insight into the underlying mechanisms of US28-related oncogenic transformation, we analyzed gene expression profiles of US28-expressing NIH-3T3 cells and the corresponding mock-transfected NIH-3T3 cells by cDNA microarray analysis. US28 WT–expressing cells showed increases in 125I-CX3CL1 binding (Fig. 1A) and inositol phosphate production (Fig. 1B), which was not apparent in mock-transfected cells. To reproducibly identify differentially expressed genes in our microarray analysis, two independent clonal cell lines, with similar reporter expression and functional characteristics (Fig. 1A and B) were used for both mock and US28-transfected NIH-3T3 cells. Analysis of the overall microarrays intensities showed highest correlation between biological duplicates (i.e., mock to mock, US28 to US28; data not shown).

Expression data of the 45,001 Affymetrix probe sets on the Mouse Genome 430 2.0 Array were normalized (RMA) and analyzed with LIMMA (21). Using a false discovery rate lower or equal to 0.02, we obtained 577 probe sets representing 556 genes (Supplementary Table S1). The most highly modulated genes are depicted in Fig. 1C. As can be seen in this figure, the observed changes in gene expression were comparable in the two different clonal mock and US28-expressing cell lines. The involvement of differentially expressed genes in biological pathways was analyzed using DAVID (23) for testing Kyoto Encyclopedia of Genes and Genomes pathways (27). The 556 genes did not present statistically enriched signaling pathways (after Benjamini correction for multiple testing). Annotation of the genes to the Kyoto Encyclopedia of Genes and Genomes pathways using the EASE software (24) highlighted pathways involved in focal adhesion, actin cytoskeleton regulation, cell cycle, and several forms of cancer but also signaling pathways such as p53, mitogen-activated protein kinase (MAPK), Wnt, and transforming growth factor β (Supplementary Table S2).

To focus on molecular mediators that contribute to the oncogenic potential of US28, we used the CancerGenes resource (28), identifying among others, Akt1, Fus, Klf6, Mdm2, and Ptgss2/Cox-2 (Table 1). In addition, because US28 has previously

http://bioinfo.mskcc.org/CancerGenes
adapted from http://jura.wi.mitle.edu/young_public/nlkb/literature_targets.xls

---

Cancer Research

Cancer Res 2009; 69: (7). April 1, 2009 2862 www.aacrjournals.org

Published OnlineFirst March 24, 2009; DOI: 10.1158/0008-5472.CAN-08-2487

Downloaded from cancerres.aacrjournals.org on November 28, 2019. © 2009 American Association for Cancer Research.
been shown to constitutively activate NF-κB signaling pathways (15), the list of modulated genes was compared with known transcriptional targets of NF-κB (Table 1). Ptgs2/Cox-2 also seemed to be one of the most strongly up-regulated NF-κB target genes. This finding of Ptgs2/Cox-2 in both cancer and NF-κB gene lists was of particular interest because COX-2 protein is highly up-regulated in various forms of cancers (29) but also induced upon HCMV-infection (20).

To validate the microarray expression data, a few genes with high fold changes were analyzed by means of qPCR. As observed in the microarray experiment, Ptgs2/Cox-2 as well as other highly differentially expressed genes (Mef2c, Cxcl12, and Tgfb2) showed a similar degree of up or down-regulation upon expression of US28 in NIH-3T3 cells (Supplementary Table S3). Because of the previously reported oncogenic potential of US28 in vivo (14), we also determined expression levels of these genes in RNA extracted from five independent US28-induced tumors derived from our xenograft model (14). Expression of US28 was confirmed in all mouse tumors by qPCR and Ptgs2/Cox-2 mRNA was highly up-regulated in US28-induced tumors, highlighting a potential important role for COX-2 during tumorigenesis.

US28 constitutive activity up-regulates COX-2 expression. COX-2 is highly up-regulated in a variety of cancers and is known to drive expression of cyclin D1 and VEGF (30). Because COX-2 is also up-regulated in HCMV-infected cells (20) and expression of US28 results in induction of cyclin D1 and VEGF expression (14), we decided to further focus on COX-2 and examine its role in US28-induced proliferative signaling and tumor formation. US28-WT-expressing cells, but not cells expressing the G-protein uncoupled mutant US28-R129A, have been shown to present a transformed phenotype in vitro (14). NIH-3T3 cells expressing US28-R129A showed comparable receptor expression levels to US28-WT–expressing cells as measured by [125I]-CX3CL1 binding (Fig. 1A) but did not show increases in inositol phosphate accumulation (Fig. 1B). Analysis of COX-2 mRNA expression by qPCR showed a 19.7 ± 1.8-fold increase in US28-WT–expressing cells compared with mock-transfected cells (Fig. 2A). Cells expressing US28-R129A revealed no significant difference (1.6 ± 0.6-fold) in COX-2 mRNA levels compared with mock-transfected cells (Fig. 2A). Similarly, US28-WT–transfected NIH-3T3 cells showed a marked increase in COX-2 protein expression compared with mock-transfected and US28-R129A–expressing cells (Fig. 2B).

US28 induces COX-2 and VEGF transcription via activation of NF-κB. To understand the molecular mechanisms resulting in the up-regulation of COX-2, signaling studies with a COX-2 promoter reporter (25) were performed in HEK 293T cells. US28 induced the human COX-2 promoter activation in a dose-dependent manner, but no increase in COX-2 promoter activity was observed in US28-R129A–expressing HEK 293T (Fig. 3A). Because the transcription of the COX-2 gene is under the control of NF-κB (31), we investigated the contribution of NF-κB in the COX-2 promoter reporter gene. US28-WT, but not US28-R129A, constitutively activated the NF-κB transcription factor in transfected HEK 293T cells (Fig. 3A). Moreover, inhibition of NF-κB activation with the IκB phosphorylation inhibitor Bay 11-7082 (5 μmol/L) resulted in a severe reduction of US28-induced COX-2 expression.
Table 1. US28-expressing cells modulate the expression of oncogenes and NF-κB transcriptional targets

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>Gene name</th>
<th>Fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer genes resource</td>
<td>Neuroepithelial cell transforming gene 1</td>
<td>11.5</td>
</tr>
<tr>
<td>Ptgs2/COX-2</td>
<td>Prostaglandin-endoperoxide synthase 2</td>
<td>6.6</td>
</tr>
<tr>
<td>Kpun1</td>
<td>Karyopherin (importin) β 1</td>
<td>6.1</td>
</tr>
<tr>
<td>Cebpβ</td>
<td>CCAAT/enhancer binding protein (C/EBP), β</td>
<td>10, 9, 2.2</td>
</tr>
<tr>
<td>Actβ</td>
<td>Actin, β</td>
<td>5.1, 3.5, 2.4</td>
</tr>
<tr>
<td>Klf6</td>
<td>Kruppel-like factor 6</td>
<td>4.1, 3.3</td>
</tr>
<tr>
<td>Ctn</td>
<td>Cortactin</td>
<td>3.4, 3.0</td>
</tr>
<tr>
<td>Fas</td>
<td>Fusion (involved in t(12;16) in malignant liposarcoma)</td>
<td>3.5</td>
</tr>
<tr>
<td>Runx1</td>
<td>Runx-related transcription factor 1</td>
<td>2.9</td>
</tr>
<tr>
<td>Akt1</td>
<td>V-akt murine thymoma viral oncogene homologue 1</td>
<td>2.7</td>
</tr>
<tr>
<td>Araf</td>
<td>V-raf murine sarcoma 3611 viral oncogene homologue</td>
<td>2.2</td>
</tr>
<tr>
<td>Mdm2</td>
<td>Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse)</td>
<td>2.2</td>
</tr>
<tr>
<td>Gli3</td>
<td>GLI-Kruppel family member GLI3</td>
<td>–3.1</td>
</tr>
<tr>
<td>Maf</td>
<td>V-maf musculoskeletal fibrosarcoma oncogene homologue (avian)</td>
<td>–3.1</td>
</tr>
<tr>
<td>Timp3</td>
<td>TIMP metalloproteinase inhibitor 3</td>
<td>–6.3, –9.2</td>
</tr>
<tr>
<td>Aff3</td>
<td>AF4/FMR2 family, member 3</td>
<td>–9.8</td>
</tr>
<tr>
<td>NF-κB transcriptional targets</td>
<td>Prostaglandin-endoperoxide synthase 2</td>
<td>6.6</td>
</tr>
<tr>
<td>Ptgs2/COX-2</td>
<td>Prostaglandin-endoperoxide synthase 2</td>
<td>6.6</td>
</tr>
<tr>
<td>Hgf</td>
<td>Hepatocyte growth factor</td>
<td>4.9, 4.8, 3.1</td>
</tr>
<tr>
<td>Serpine1</td>
<td>Serine (or cysteine) peptidase inhibitor, clade E, member 1</td>
<td>4.2</td>
</tr>
<tr>
<td>Nrla2</td>
<td>Nuclear receptor subfamily 4, group A, member 2</td>
<td>3.8, 3.6, 2.8</td>
</tr>
<tr>
<td>Gadd45b</td>
<td>Growth arrest and DNA-damage-inducible 45 β</td>
<td>2.8</td>
</tr>
<tr>
<td>Csf1</td>
<td>Colony stimulating factor 1 (macrophage)</td>
<td>2.6</td>
</tr>
<tr>
<td>Cflar</td>
<td>CASP8 and FADD-like apoptosis regulator</td>
<td>2.3</td>
</tr>
<tr>
<td>C3</td>
<td>Complement component 3</td>
<td>–2.8</td>
</tr>
<tr>
<td>Mmp9</td>
<td>Matrix metalloproteinase 9</td>
<td>–2.8, –6.8</td>
</tr>
<tr>
<td>Sox9</td>
<td>SRY-box containing gene 9</td>
<td>–2.9</td>
</tr>
</tbody>
</table>

Abbreviations: C/EBP, CAAT/enhancer binding protein; TIMP, tissue inhibitor of metalloproteinase.

To further assess the role of NF-κB in the US28-induced COX-2 expression, we used two truncated COX-2 promoter reporter genes that do not contain sequential NF-κB binding sites (25). 5'-Deletions of the distal and both distal and proximal NF-κB binding sites reduced the US28-induced constitutive activation of the COX-2 promoter by respectively 30% and 80% compared with the nondeleted promoter (Fig. 3C). Because COX-2 is known to drive expression of VEGF (30), shown to be up-regulated upon expression of US28 (14), we investigated the role of NF-κB in VEGF promoter activity using the NF-κB inhibitor Bay 11-7082. As seen for the US28-induced COX-2 promoter activity, the US28-induced VEGF promoter activation was markedly inhibited by Bay 11-7082, highlighting the involvement of NF-κB in this process (Fig. 3D).

US28 induces COX-2 expression in HCMV-infected cells. Infection of cells with HCMV is associated with the activation of various signaling pathways linked to inflammation, including increased expression of COX-2 (32). Because US28 induced COX-2 expression in transfected cells, we examined the role of US28 in a viral setting. To this end, we used a HCMV deletion virus derived from the AD169 strain that does not contain the sequence encoding for US28 (AD169-DUS28). Human foreskin fibroblasts were infected with either mock, AD169-WT, or the deletion mutant AD169-DUS28 (multiplicity of infection, 3). Eight hours postinfection, only cells infected with the WT virus presented expression of US28 mRNA (Fig. 4A). As expected, the deletion mutant (Δ) did not induce the expression of US28 mRNA. Radioligand binding studies showed that also on the protein level, only cells infected with the AD169-WT virus expressed US28 on their cell surface (Fig. 4B).

In accordance with earlier findings (32), COX-2 mRNA levels were clearly up-regulated in cells infected with the WT virus 8 h.
postinfection, compared with mock-infected cells (Fig. 4C). In cells infected with AD169-ΔUS28, COX-2 mRNA levels were markedly reduced, highlighting a role for US28 in the viral induction of COX-2. The observed decrease in COX-2 mRNA in AD169-ΔUS28-infected cells was not attributed to impairment in viral IE expression of this mutant strain (data not shown), indicating that the viral replication abilities of both viruses were similar. Because US28 is able to constitutively activate NF-κB (15), we also tested whether this was the case in the HCMV context. Infection of cells with AD169-WT was clearly associated with increased activation of NF-κB as measured using a NF-κB reporter gene (Fig. 4D). When infecting cells with the US28 deletion mutant, we found that the HCMV-induced NF-κB activation was markedly impaired compared with cells infected with the WT virus (Fig. 4D). This indicates that upon HCMV infection, US28 activates NF-κB, regulating in turn expression of its transcriptional target COX-2.

COX-2 plays an important role in US28-mediated tumor formation. We have previously shown that US28 up-regulates VEGF expression in stably transfected NIH-3T3 cells (14). Because VEGF expression is in part regulated by COX-2 (30), we tested in vitro the effect of the COX-2-specific nonsteroidal anti-inflammatory drug (NSAID) Celecoxib on the US28-induced secretion of VEGF. When culturing US28-expressing NIH-3T3 cells with Celecoxib (25 μmol/L), VEGF secretion was significantly reduced (52% ± 2%; P < 0.001), indicating the involvement of COX-2 in the US28-induced proangiogenic phenotype (Fig. 5A). As Celecoxib was able to inhibit in vitro an important angiogenic factor involved in US28-induced tumor formation, it was also used in vivo to examine the contribution of COX-2 during tumorigenesis. Celecoxib treatment was started 1 day before the injection of US28-stably transfected NIH-3T3 cells into nude mice by feeding the animals with chow containing 1,500 ppm Celecoxib (33). As previously described, all control mice injected with US28-expressing cells developed tumors larger than 50 mm³ within 3 weeks. Yet, at this time point, Celecoxib-fed mice showed a severely delayed onset in tumor formation (Fig. 5B). Developing tumors reached the size of 50 mm³ between 21 and 39 days postinjection, whereas for the control group, tumor formation occurred between 14 and 21 days postinjection. Celecoxib also increased the tumor doubling time. Untreated mice injected with US28-expressing cells displayed an average tumor doubling time of 3.4 ± 0.3 days, whereas Celecoxib-treated mice presented a longer doubling time of 6.4 ± 0.4 days. When xenografts had reached their maximum size and animals were sacrificed, no significant changes in VEGF mRNA levels were apparent between the untreated and Celecoxib-treated tumors (data not shown). To measure effects of Celecoxib on the angiogenic activity in US28-induced tumors, we examined CD31 expression by immunohistochemistry. Xenografts derived from stably transfected NIH-3T3 cells lines show highest growth activity in the outer cell layers rather than at the center of the tumor, which can become necrotic when tumors become large. As expected, the angiogenic activity in the untreated US28-derived tumors was

![Figure 3](https://example.com/figure3.png)

**Figure 3.** US28 activates the COX-2 and VEGF promoters via NF-κB. A, HEK 293T cells transiently transfected with increasing amounts of US28 show a dose-dependent activation of the human COX-2 promoter luciferase reporter gene. The human COX-2 promoter and the transcription factor NF-κB are activated after transfection of US28-WT but not with the G-protein uncoupled mutant US28-R129A. RLU, relative light units. B, US28-WT–induced COX-2 promoter activation is inhibited by the NF-κB inhibitor Bay 11-7082 (5 μmol/L). C, the US28-WT–induced COX-2 promoter activity is reduced when one and in particular both NF-κB binding sites are removed in 5'-deletion mutants of the human COX-2 promoter. D, US28-WT–induced VEGF promoter activation is inhibited by the NF-κB inhibitor Bay 11-7082 (5 μmol/L).
clearly apparent in the outer area of the malignancies with a dense localization of CD31-positive blood vessels (Fig. 5C). Interestingly, the Celecoxib-treated tumors presented a lower staining intensity of CD31 and a less dense distribution of newly formed blood vessels compared with the untreated group. As such, COX-2 inhibition by Celecoxib delayed the onset of US28-induced tumors and slowed their overall growth by repressing angiogenic activity.

Discussion

Infection of cells with herpesviruses is known to alter cellular gene expression and cell function. Functional genomic analyses of herpesvirus-infected cells have led to the identification of genes that contribute to viral pathogenesis, including induction of tumorigenic events (18–20). In view of the reported oncomodulatory potential of HCMV (6) and particularly the observed oncogenic properties of the HCMV-encoded chemokine receptor US28 (14), we subjected US28-expressing cells to a detailed microarray analysis. As anticipated, US28 and mock-transfected NIH-3T3 cells differentially express genes involved in oncogenic events (e.g., renal cell carcinoma, prostate cancer, and melanoma). Significantly modulated genes are implicated in cell cycle, p53, and MAPK pathways (Supplementary Table S2), all associated with proliferation (34–37). Also, modulation of genes involved in focal adhesion and actin cytoskeleton rearrangement, both of importance in tissue invasion and metastasis (38), is observed. Although these pathways are not statistically enriched in a DAVID analysis, they are correlated to the modulated genes using EASE, providing mechanistic insights on how US28 may induce transformation and tumor development. Another analysis of the microarray data, focusing on cancer-related genes and NF-κB transcriptional targets, reveals modulation of genes involved in several forms of cancer that have previously been linked to HCMV infection such as colorectal and breast cancers (e.g., renal cell carcinoma, prostate cancer, and melanoma) and also up-regulates COX-2 expression within a few hours after infection (32).

Because US28 constitutively activates NF-κB signaling, it is not surprising to observe modulation of NF-κB target genes in US28-expressing cells (Fig. 1D). One of such genes under control of NF-κB is COX-2 (31), which seems to be highly up-regulated in US28-expressing cells and tumors (Table 1). COX-2 is of specific interest because it is a key mediator of inflammation and it is now well-established that it contributes to the pathogenesis of several forms of cancer. This enzyme is commonly expressed in both premalignant lesions and malignant tumors of e.g., colon, lung, head, neck, and breast (29). In view of the role of COX-2 in tumor development and its up-regulation in herpesvirus-infected cells, this enzyme has been suggested to participate in neoplasia induced by some of the oncogenic herpesviruses, including KSHV and EBV (39). Of interest, HCMV possesses oncomodulatory properties (6) and also up-regulates COX-2 expression within a few hours after infection (32).

Because our microarray studies reveal marked increases in COX-2 expression in US28-expressing cells, and US28 was shown earlier to up-regulate expression of VEGF and cyclin D1 (14), both known to be regulated by COX-2 (30), COX-2 is a likely determinant in the US28-induced tumor formation. Our studies show that US28 expression is associated with up-regulation of COX-2 at both the mRNA and protein levels via activation of NF-κB (Figs. 2 and 3). As expected, NF-κB is also implicated in the US28-induced VEGF promoter activity (Fig. 3D). The G-protein uncoupled mutant US28-R129A does not activate NF-κB nor up-regulate COX-2 expression (Fig. 2 and 3), indicating a role for G proteins in the US28-mediated COX-2 up-regulation (15).

To further show the contribution of COX-2 in the US28-induced tumor formation, we performed in vitro assays and intervention studies in our US28 tumor xenograft model using the nonsteroidal anti-inflammatory drug COX-2 inhibitor Celecoxib (Fig. 5). Several clinical studies have provided encouraging evidence of preventive effects of nonsteroidal anti-inflammatory drugs in cancers of colon, lung, breast, and prostate (40). Although some of these drugs were associated with cardiovascular toxicity, recent studies presented Celecoxib as one of the coxibs possessing least side effects (41). Various animal studies reported effective inhibition of cell growth in vivo in tumor growth in vivo upon Celecoxib treatment (33, 42, 43). In vivo, Celecoxib treatment of mice injected with US28-expressing cells severely delays and impairs tumor formation.
Figure 5. Celecoxib impairs US28 oncogenic potential. A, release of VEGF in the culture medium of US28 stably transfected NIH-3T3 cells is partly inhibited by Celecoxib (25 μmol/L). *** P < 0.0001. B, Celecoxib-treated mice injected with US28-expressing cells (○) develop tumors bigger than 50 mm³ later and at a slower rate than control mice (○). Twenty days postinjection of US28-expressing cells into nude mice, control mice present extensive tumor formation, whereas the Celecoxib-treated group (1,500 ppm) is still devoid of tumors. C, representative CD31 staining in US28-induced tumors from control and Celecoxib-treated mice. D, schematic representation of US28-induced COX-2 up-regulation and role during tumor formation. US28 is expressed at the cell surface of HCMV-infected cells and increases COX-2 expression via NF-κB. COX-2 activity leads to PGE2 release that can bind to its cognate receptors EP1-4 and subsequently induces VEGF and Cyclin D1 transcription. This results in angiogenesis and tumor formation that can be inhibited by Celecoxib.
After 3 weeks, no tumors are formed in the Celecoxib-treated mice, whereas tumors are apparent in the control group, indicating that COX-2 expression is of importance in early tumorigenic events induced by US28. But in the long term, Celecoxib-treated mice also present tumors, indicating that COX-2 is not the sole factor responsible for US28-induced tumor formation. Importantly, Celecoxib treatment reduces the growing rate of the tumor compared with untreated mice ($P < 0.001$ in Log-rank test), confirming the involvement of COX-2 in tumor development. In addition, Celecoxib impairs the angiogenic phenotype induced by US28, both in vitro by significantly ($P < 0.0001$) decreasing the production of VEGF in US28-expressing cells, and in vivo, by reducing angiogenic activity in US28-derived xenografts. As such, the impairment of the COX-2/VEGF axis by Celecoxib could be accounted for the decreased angiogenesis and subsequent slower development of the tumors in vivo. It is important to note that our microarray analysis indicates that other oncogenes beside COX-2 are likely to be implicated in US28-induced tumor progression. The observed inhibitory effect of Celecoxib on tumor formation are most likely attributed to the functional inhibition of COX-2, although some COX-2 independent effects by Celecoxib have been reported (44). Other targets of Celecoxib include, e.g., Cyclin D1 (45) and NF-κB (46), both up-regulated in US28-transfected cells. Thus, impairment of US28-induced tumorigenesis by Celecoxib, either through direct or indirect COX-2 inhibition, involves inhibition of proliferative signaling proteins that are constitutively activated by US28.

Cells infected with the AD169 strain devoid of US28 (AD169-ΔUS28) show a reduced activation of NF-κB and up-regulation of COX-2 compared with cells infected with the WT virus (Fig. 4). In vivo, US28 expression has been shown in lung transplant immunosuppressed patients presenting HCMV primary infection or reactivation (16). Because of the US28-mediated increases in NF-κB activation and COX-2 up-regulation in infected cells in vitro, US28 may be implicated in virus-associated pathologies by further enhancing and/or contributing to increases in COX-2 expression.

We have previously shown that US28 constitutive activity is mediated by Gαq and G12/13 proteins (14, 15). The constitutive activation of COX-2 or VEGF promoter by US28 could not be modulated by any of the CC and CX3C chemokines (CCL2, CCL5, and CX3CL1) known to bind this viral G-protein coupled receptor (data not shown). Ligand-stimulation of US28 has however been shown to promote cell migration via activation of G12/13 proteins (47). As such, the Gαq pathway may be preferentially activated constitutively by US28 during oncogenic transformation, whereas the ligand-induced signaling may be favorable for the migration of US28-expressing cells. We therefore postulate that upon HCMV infection, US28 is expressed and constitutively activates NF-κB in a ligand-independent manner. US28 potentially activates Gαq and G12/13 proteins (47) to induce the expression of inflammatory proteins such as COX-2 (31). This enzyme is responsible for the synthesis of PGE2, which through activation of its cognate receptors EP1–4 leads to a subsequent enhancement of cell proliferation (Cyclin D1) and promotion of angiogenesis (VEGF; ref. 30). US28-dependent increases of at least COX-2 early after infection might be sufficient to catalyze inflammatory processes, which may contribute to or enhance tumor formation (Fig. 5D). Hence, the development of HCMV-related proliferative diseases might in part be ascribed to the ability of US28 to modulate expression of COX-2.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 7/3/08; revised 12/12/08; accepted 1/28/09; published OnlineFirst 3/24/09.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. M. Fresno and Pfzer for providing respectively the human COX-2 promoter lucase reporter gene plasmids and the COX-2 inhibitor Celecoxib, and Dr. H.F. Vischer for the creation of the Fig. 5D artwork.

References

Role of COX-2 in US28-Induced Tumor Formation


The Human Cytomegalovirus–Encoded Chemokine Receptor US28 Promotes Angiogenesis and Tumor Formation via Cyclooxygenase-2

David Maussang, Ellen Langemeijer, Carlos P. Fitzsimons, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-08-2487

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2009/03/23/0008-5472.CAN-08-2487.DC1

Cited articles
This article cites 46 articles, 12 of which you can access for free at:
http://cancerres.aacrjournals.org/content/69/7/2861.full#ref-list-1

Citing articles
This article has been cited by 10 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/69/7/2861.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/69/7/2861.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.